Bioequivalence Study of Nefopam Hydrochloride 30mg Tablets vs Acupan® 30mg Tablets in Healthy Subjects

NCT03311022 | Completed Phase 1

• 2 other identifiers: BKE138142015-003810-26
• Study Type: interventional
• Target: 29
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the bioavailability of Nefopam Hydrochloride 30mg Tablets (test product) and Acupan® 30mg Tablets (reference product).

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Maximum measurable plasma concentration (Cmax)

  Cmax and AUC0-t will be used to calculate bioequivalence of the test product (Treatment 1) vs reference product (Treatment 2).

  0 to 48 hours post-dose

• Area under the plasma concentration versus time curve from drug administration to last observed concentration at time t (AUC0-t)

  Cmax and AUC0-t will be used to calculate bioequivalence of the test product (Treatment 1) vs reference product (Treatment 2).

  0 to 48 hours post-dose

Secondary Outcomes (5)

• Adverse events, including laboratory parameters.

  18 days

• Time of maximum measured plasma concentration (Tmax)

  0 to 48 hours post-dose

• Elimination rate constant (Kel)

  0 to 48 hours post-dose

• Elimination or terminal half-life (t1/2)

  0 to 48 hours post-dose

• Area under the plasma concentration versus time curve from time zero extrapolated to infinity (AUC0-∞)

  0 to 48 hours post-dose

Study Arms (2)

Treatment 1

EXPERIMENTAL

One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.

Drug: Nefopam Hydrochloride 30mg Tablets

Treatment 2

ACTIVE COMPARATOR

One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.

Drug: Acupan® 30mg Tablets

Interventions

Nefopam Hydrochloride 30mg Tablets DRUG

Treatment 1

Acupan® 30mg Tablets DRUG

Treatment 2

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female volunteers aged 18-45 (both inclusive), as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening.
• Non-smokers from at least three months before receiving the first dose of study drug and for the duration of the study.
• Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.
• Able to voluntarily provide written informed consent to participate in the study.
• Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
• Female volunteers of child-bearing potential and less than one year post-menopausal must have a negative serum pregnancy test and be non-lactating.
• Female volunteers who have been post-menopausal for more than one year and have elevated serum follicle stimulating hormone (FSH) or are treated with hormone replacement therapy (HRT) or female volunteers who have been permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy).
• Female volunteers of child-bearing potential who are sexually active must use a highly effective method of contraception throughout the study and for 30 days after completion of the study. Acceptable highly effective methods include: established use of oral, injected or implanted hormonal methods of contraception (resulting in a failure rate of less than 1% per year); placement of an intrauterine device or intrauterine system; true abstinence where this is already established as the volunteer's preferred and usual lifestyle; a male partner who has undergone sterilisation (provided that they are the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success).
• Male volunteers must not donate sperm during the study and for 90 days after completion of the study.
• Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
• The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study.

You may not qualify if:

• Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, urogenital (including benign prostatic hypertrophy), haematological, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or current infection.
• Volunteers with, or at risk of, urinary retention.
• Laboratory values at screening which are deemed to be clinically significant, unless agreed in advance by the Sponsor's Medical Representative and Principal Investigator.
• Female volunteers who are pregnant or lactating.
• Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
• Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
• Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
• Any clinically significant illness within 30 days prior to study drug administration.
• Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol.
• Volunteers who have a history or presence of any significant drug allergy, including a history of hypersensitivity to nefopam hydrochloride, any related drugs, or any of the excipients contained in the formulations.
• Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 14 days prior to study drug administration until the end of the study, with the exception of Investigator approved contraceptives and HRT and paracetamol.
• Volunteers with inadequate venous access to allow collection of blood samples as required by this protocol.
• Strenuous exercise, as judged by the Investigator, within 72 hours prior to screening, within 72 hours prior to study drug administration and for the duration of the study until after the post-study medical.
• Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males.
• Consumption of alcoholic beverages within 48 hours prior to study drug administration and during study confinement.

Sponsors & Collaborators

• Galen Limited: lead

Study Sites (1)

BioKinetic Europe Ltd

Belfast, BT2 7BA, United Kingdom

Location

MeSH Terms

Interventions

Nefopam

Intervention Hierarchy (Ancestors)

Oxazocines; Azocines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Neil Fawkes, MBChB

  BioKinetic Europe Ltd

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 11, 2017
• First Posted: October 16, 2017
• Study Start: November 6, 2015
• Primary Completion: December 21, 2015
• Study Completion: December 21, 2015
• Last Updated: October 16, 2017

Record last verified: 2017-10

Locations

GB (1)